CRDL
Cardiol Therapeutics Inc.
Price Chart
Latest Quote
$1.98
+0.04 (+1.80%)
Current Price
| Previous Close | $1.94 |
| Open | $1.92 |
| Day High | $1.98 |
| Day Low | $1.88 |
| Volume | 703,326 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 116.82M |
| Total Debt | $77K |
| Cash Equivalents | $18.81M |
| Net Income | $-24.58M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $230.72M |
| EPS (TTM) | $-0.25 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $204.75M |
| Income | $-24.58M |
| Book/sh | $0.15 |
| Cash/sh | $0.22 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 5.01 |
| Current Ratio | 5.55 |
| Debt/Eq | 0.45 |
Returns & Margins
| ROA | -90.92% |
| ROE | -190.18% |
Ownership
| Insider Ownership | 2.37% |
| Institutional Ownership | 25.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.28 |
| P/B | 13.26 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.52 |
Technical Indicators
| SMA20 | $1.71 |
| SMA50 | $1.35 |
| SMA200 | $1.18 |
| RSI | 74.40 |
| ATR | 0.1583 |
| Shares Float | 92.07M |
| Short Float | 2.03% |
| Short Ratio | 2.03 |
| Volatility | 0.47 |
| Rel Volume | 0.47 |
Performance History
| Week | +6.18% |
| Month | +63.22% |
| Quarter | +61.89% |
| 6 Months | +93.63% |
| YTD | +98.69% |
| Year | +76.34% |
| 3 Years | +97.50% |
| 5 Years | -31.80% |
| 10 Years | -47.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $1.98 | 703,326 |
| 2026-08-27 | $2.06 | 1,835,000 |
| 2026-08-26 | $2.14 | 4,527,100 |
| 2026-08-25 | $2.00 | 2,164,600 |
| 2026-08-24 | $1.86 | 1,011,700 |
| 2026-08-21 | $1.86 | 753,300 |
| 2026-08-20 | $1.88 | 1,526,900 |
| 2026-08-19 | $1.96 | 1,754,000 |
| 2026-08-18 | $1.89 | 1,596,800 |
| 2026-08-17 | $1.80 | 2,334,800 |
| 2026-08-14 | $1.80 | 1,725,500 |
| 2026-08-13 | $1.71 | 2,140,800 |
| 2026-08-12 | $1.52 | 790,700 |
| 2026-08-11 | $1.50 | 776,200 |
| 2026-08-10 | $1.47 | 1,519,500 |
| 2026-08-07 | $1.42 | 327,100 |
| 2026-08-06 | $1.36 | 789,900 |
| 2026-08-05 | $1.34 | 1,067,500 |
| 2026-08-04 | $1.36 | 1,535,700 |
| 2026-08-03 | $1.31 | 778,600 |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
đ° Latest News
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-08-25T13:40:03Z
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Zacks âĸ 2026-08-24T16:00:04Z
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
MarketBeat âĸ 2026-08-12T12:01:58Z
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Simply Wall St. âĸ 2026-05-15T16:22:54Z
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
MT Newswires âĸ 2026-04-28T12:07:56ZCardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
MarketBeat âĸ 2026-04-15T10:15:39Z
Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
MT Newswires âĸ 2026-04-01T18:24:19ZCardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
MarketBeat âĸ 2026-03-08T23:02:26Z
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks âĸ 2026-03-03T13:07:00Z
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long
Simply Wall St. âĸ 2026-01-12T15:38:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $24,741,562 | $29,038,893 | $21,474,925 | $29,802,581 |
| Other Income Expense | $-165,091 | $1,734,699 | $-274,878 | $6,609,709 |
| Net Non Operating Interest Income Expense | $523,725 | $860,383 | $1,469,704 | $892,315 |
| Operating Expense | $24,741,562 | $29,038,893 | $21,474,925 | $29,802,581 |
| General And Administrative Expense | $14,560,923 | $18,667,337 | $11,219,416 | $16,131,191 |
| Other Non Operating Income Expenses | - | $20,348 | $107,960 | $118,561 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Net Interest Income | $523,725 | $860,383 | $1,469,704 | $892,315 |
| Interest Income | $523,725 | $860,383 | $1,469,704 | $892,315 |
| Normalized Income | $-24,217,837 | $-28,158,162 | $-19,897,261 | $-28,791,705 |
| Net Income From Continuing And Discontinued Operation | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Net Income Common Stockholders | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Net Income | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Net Income Including Noncontrolling Interests | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Net Income Continuous Operations | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Pretax Income | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Interest Income Non Operating | $523,725 | $860,383 | $1,469,704 | $892,315 |
| Operating Income | $-24,741,562 | $-29,038,893 | $-21,474,925 | $-29,802,581 |
| Depreciation Amortization Depletion Income Statement | $73,528 | $269,010 | - | - |
| Depreciation And Amortization In Income Statement | $73,528 | $269,010 | - | - |
| Amortization Of Intangibles Income Statement | $0 | $151,665 | - | - |
| Depreciation Income Statement | $73,528 | $117,345 | - | - |
| Per Share | ||||
| Diluted EPS | $-0.28 | $-0.37 | $-0.32 | $-0.35 |
| Basic EPS | $-0.28 | $-0.37 | $-0.32 | $-0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,502,943 | $-30,484,234 | $-20,913,027 | $-36,135,178 |
| Total Unusual Items | $-165,091 | $1,714,351 | $-382,838 | $6,491,148 |
| Total Unusual Items Excluding Goodwill | $-165,091 | $1,714,351 | $-382,838 | $6,491,148 |
| Reconciled Depreciation | $73,528 | $269,010 | $179,060 | $158,551 |
| EBITDA (Bullshit earnings) | $-24,668,034 | $-28,769,884 | $-21,295,865 | $-29,644,031 |
| EBIT | $-24,741,562 | $-29,038,893 | $-21,474,925 | $-29,802,581 |
| Diluted Average Shares | $62,718,078 | $51,599,335 | $46,476,970 | $45,065,925 |
| Basic Average Shares | $62,718,078 | $51,599,335 | $46,476,970 | $45,065,925 |
| Diluted NI Availto Com Stockholders | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Gain On Sale Of Security | $-165,091 | $1,714,351 | $-382,838 | $6,491,148 |
| Amortization | $0 | $151,665 | - | - |
| Research And Development | $10,107,111 | $10,102,547 | $10,255,509 | $13,671,390 |
| Selling General And Administration | $14,560,923 | $18,667,337 | $11,219,416 | $16,131,191 |
| Other Gand A | $7,910,662 | $9,354,751 | $11,219,416 | $16,131,191 |
| Salaries And Wages | $6,650,261 | $9,312,586 | - | - |
Fetched: 2026-08-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,889,581 | $17,828,885 | $20,213,665 | $37,424,056 |
| Total Assets | $17,029,636 | $22,973,312 | $26,460,545 | $44,721,681 |
| Total Non Current Assets | $85,143 | $141,019 | $394,679 | $425,771 |
| Current Assets | $16,944,493 | $22,832,293 | $26,065,866 | $44,295,910 |
| Prepaid Assets | $1,340,284 | $523,803 | $678,766 | $1,072,764 |
| Receivables | $163,083 | $260,724 | $201,784 | $346,215 |
| Other Receivables | $122,905 | $188,361 | $98,867 | $194,864 |
| Accounts Receivable | $40,178 | $72,362 | $102,917 | $151,352 |
| Cash Cash Equivalents And Short Term Investments | $15,441,125 | $22,047,767 | $25,185,316 | $42,876,930 |
| Cash And Cash Equivalents | $15,441,125 | $22,047,767 | $25,185,316 | $42,876,930 |
| Goodwill And Other Intangible Assets | - | $0 | $151,665 | $212,548 |
| Other Intangible Assets | - | - | $151,665 | $212,548 |
| Debt | ||||
| Total Debt | $90,500 | $114,299 | $125,697 | $52,539 |
| Long Term Debt And Capital Lease Obligation | $62,853 | $90,500 | $114,299 | $16,167 |
| Current Debt And Capital Lease Obligation | $27,648 | $23,799 | $11,397 | $36,372 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,140,055 | $5,144,427 | $6,095,215 | $7,085,077 |
| Total Non Current Liabilities Net Minority Interest | $62,853 | $90,500 | $114,299 | $16,167 |
| Current Liabilities | $4,077,203 | $5,053,927 | $5,980,915 | $7,068,910 |
| Other Current Liabilities | $1,541,372 | - | $171,722 | $302,743 |
| Payables And Accrued Expenses | $2,508,183 | $5,030,128 | $5,797,796 | $6,729,795 |
| Equity | ||||
| Common Stock Equity | $12,889,581 | $17,828,885 | $20,365,330 | $37,636,604 |
| Total Equity Gross Minority Interest | $12,889,581 | $17,828,885 | $20,365,330 | $37,636,604 |
| Stockholders Equity | $12,889,581 | $17,828,885 | $20,365,330 | $37,636,604 |
| Retained Earnings | $-153,622,589 | $-129,239,661 | $-102,795,850 | $-82,515,751 |
| Other Equity Interest | - | - | $2,536,332 | $2,536,332 |
| Other | ||||
| Ordinary Shares Number | $72,283,880 | $59,559,910 | $47,118,065 | $46,173,759 |
| Share Issued | $72,283,880 | $59,559,910 | $47,118,065 | $46,173,759 |
| Tangible Book Value | $12,889,581 | $17,828,885 | $20,213,665 | $37,424,056 |
| Invested Capital | $12,889,581 | $17,828,885 | $20,365,330 | $37,636,604 |
| Working Capital | $12,867,290 | $17,778,366 | $20,084,951 | $37,227,000 |
| Capital Lease Obligations | $90,500 | $114,299 | $125,697 | $52,539 |
| Total Capitalization | $12,889,581 | $17,828,885 | $20,365,330 | $37,636,604 |
| Additional Paid In Capital | $20,969,327 | $17,770,255 | $13,544,660 | $11,237,885 |
| Capital Stock | $145,542,843 | $129,298,292 | $107,080,188 | $106,378,138 |
| Common Stock | $145,542,843 | $129,298,292 | $107,080,188 | $106,378,138 |
| Long Term Capital Lease Obligation | $62,853 | $90,500 | $114,299 | $16,167 |
| Current Capital Lease Obligation | $27,648 | $23,799 | $11,397 | $36,372 |
| Net PPE | $85,143 | $141,019 | $243,014 | $213,223 |
| Accumulated Depreciation | $-630,604 | $-557,076 | $-473,513 | $-355,336 |
| Gross PPE | $715,748 | $698,095 | $716,527 | $568,559 |
| Leases | $171,052 | $171,052 | $171,052 | $171,052 |
| Other Properties | $370,725 | $370,725 | $404,507 | $268,339 |
| Machinery Furniture Equipment | $173,970 | $156,318 | $140,968 | $129,167 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-08-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,216,517 | $-18,083,879 | $-18,201,108 | $-19,679,346 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,198,864 | $-18,068,529 | $-18,154,740 | $-19,625,482 |
| Cash Flow From Continuing Operating Activities | $-17,198,864 | $-18,068,529 | $-18,154,740 | $-19,625,482 |
| Operating Gains Losses | $-92,071 | $-1,534,436 | $-680,440 | $-5,627,461 |
| Investing Activities | ||||
| Capital Expenditure | $-17,653 | $-15,350 | $-46,368 | $-53,864 |
| Investing Cash Flow | $-17,653 | $-15,350 | $-46,368 | $-53,864 |
| Cash Flow From Continuing Investing Activities | $-17,653 | $-15,350 | $-46,368 | $-53,864 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,563,152 | $15,397,076 | $0 | $0 |
| Financing Cash Flow | $11,203,997 | $13,583,615 | $-39,925 | $-38,886 |
| Cash Flow From Continuing Financing Activities | $11,203,997 | $13,583,615 | $-39,925 | $-38,886 |
| Net Other Financing Charges | $-343,930 | $-1,911,498 | - | - |
| Net Common Stock Issuance | $11,563,152 | $15,397,076 | $0 | $0 |
| Common Stock Issuance | $11,563,152 | $15,397,076 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-39,925 | $-29,944 | $-39,925 | $-38,886 |
| End Cash Position | $15,441,125 | $22,047,767 | $25,185,316 | $42,876,930 |
| Beginning Cash Position | $22,047,767 | $25,185,316 | $42,876,930 | $60,490,038 |
| Effect Of Exchange Rate Changes | $-594,122 | $1,362,714 | $549,419 | $2,105,124 |
| Changes In Cash | $-6,012,520 | $-4,500,264 | $-18,241,034 | $-19,718,232 |
| Proceeds From Stock Option Exercised | $24,701 | $127,982 | $0 | $0 |
| Net Issuance Payments Of Debt | $-39,925 | $-29,944 | $-39,925 | $-38,886 |
| Net Long Term Debt Issuance | $-39,925 | $-29,944 | $-39,925 | $-38,886 |
| Long Term Debt Payments | $-39,925 | $-29,944 | $-39,925 | $-38,886 |
| Net PPE Purchase And Sale | $-17,653 | $-15,350 | $-46,368 | $-53,864 |
| Purchase Of PPE | $-17,653 | $-15,350 | $-46,368 | $-53,864 |
| Change In Working Capital | $-528,726 | $-671,645 | $-393,570 | $4,144,237 |
| Change In Payables And Accrued Expense | $190,116 | $-767,669 | $-931,999 | $3,226,272 |
| Change In Prepaid Assets | $-816,482 | $154,964 | $393,998 | $970,648 |
| Change In Receivables | $97,640 | $-58,940 | $144,431 | $-52,682 |
| Changes In Account Receivables | $32,184 | $30,555 | $48,434 | $-103,955 |
| Other Non Cash Items | $16,126 | $18,547 | $23,342 | $385,314 |
| Stock Based Compensation | $7,715,206 | $10,293,807 | $2,996,966 | $3,614,435 |
| Depreciation Amortization Depletion | $73,528 | $269,010 | $179,060 | $158,551 |
| Depreciation And Amortization | $73,528 | $269,010 | $179,060 | $158,551 |
| Amortization Cash Flow | $0 | $151,665 | $60,883 | $60,883 |
| Amortization Of Intangibles | $0 | $151,665 | $60,883 | $60,883 |
| Depreciation | $73,528 | $117,345 | $118,178 | $97,668 |
| Gain Loss On Investment Securities | $-686,193 | $-171,722 | $-131,021 | $-3,522,337 |
| Net Foreign Currency Exchange Gain Loss | $594,122 | $-1,362,714 | $-549,419 | $-2,105,124 |
| Net Income From Continuing Operations | $-24,382,928 | $-26,443,812 | $-20,280,099 | $-22,300,557 |
| Change In Inventory | - | - | $0 | $0 |
Fetched: 2026-08-18